A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

"Potential conflict of interest: Drs. Russo and Adams received grants from Novartis. Dr. Phatak is on the speakers' bureau of Novartis. Dr. Brissot advises, is on the speakers' bureau of, and received grants from Novartis. Dr. Bonkovsky advises Boehringer-Ingelheim. He is a consultant for Clinuvel. He advises and received grants from Novartis. He is a consultant for and is on the speakers' bureau of Lindbeck. He also received grants from Vertex."

"This study was sponsored by Novartis Pharmaceuticals Corp. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Rebecca Helson for medical editorial assistance with this manuscript. Dr. Yves Deugnier and Dr. Fabrice Lainé from Pontchaillou University Hospital are also acknowledged for significant contributions to the conduct of this study. This study was sponsored by Novartis Pharmaceuticals Corporation. Potential conflict of interest: Drs. Russo and Adams received grants from Novartis. Dr. Phatak is on the speakers' bureau of Novartis. Dr. Brissot advises, is on the speakers' bureau of, and received grants from Novartis. Dr. Bonkovsky advises Boehringer-Ingelheim. He is a consultant for Clinuvel. He advises and received grants from Novartis. He is a consultant for and is on the speakers' bureau of Lindbeck. He also received grants from Vertex."